

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
31 January 2002 (31.01.2002)

PCT

(10) International Publication Number  
WO 02/08178 A1

(51) International Patent Classification<sup>7</sup>: C07C 311/51, A61K 31/18 // A61P 3/00

(74) Agent: HÖGLUND, Lars; Biovitrum AB, S-112 76 Stockholm (SE).

(21) International Application Number: PCT/SE01/01651

(22) International Filing Date: 19 July 2001 (19.07.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0002754-0 21 July 2000 (21.07.2000) SE

(71) Applicant (for all designated States except US): BIOVITRUM AB [SE/SE]; S-112 76 Stockholm (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): JOSSAN, Sukhwinder [IN/SE]; Skrinvägen 8, S-756 47 Uppsala (SE). NILSSON, Björn, M. [SE/SE]; Djäknegratan 15:650, S-754 23 Uppsala (SE). SAKARIASSEN, Kjell, S. [NO/SE]; Hässelby Strandväg 74, S-165 65 Hässelby (SE). SVARTENGREN, Jan [SE/SE]; Väderkvarns-gatan 48 A, S-753 26 Uppsala (SE).

(81) Designated States (national): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/08178 A1

(54) Title: NEW COMBINATION OF SEROTONIN AGONIST (5HT<sub>2</sub>) AND ANTAGONIST (5HT<sub>6</sub>) AS PHARMACEUTICAL FORMULATION

(57) Abstract: The invention relates to a method of preventing or treating a disease related to the 5-HT<sub>2C</sub> receptor and the 5-HT<sub>6</sub> receptor, comprising administering to a human or animal subject in need thereof a 5-HT<sub>2C</sub> receptor agonist and a 5-HT<sub>6</sub> receptor antagonist in sufficient amounts to provide a therapeutic affect. The invention also relates to a pharmaceutical composition comprising an effective amount of a combination of a 5-HT<sub>2C</sub> receptor agonist and a 5-HT<sub>6</sub> receptor antagonist, and optionally a pharmaceutically acceptable carrier.

NEW COMBINATION OF SEROTONIN AGONIST (5HT<sub>2</sub>) AND  
ANTAGONIST (5HT<sub>6</sub>) AS PHARMACEUTICAL FORMULATION

## TECHNICAL FIELD

5

The present invention relates to the prophylaxis or treatment of a 5-HT<sub>2C</sub> and a 5-HT<sub>6</sub> receptor-related disease. In addition, the invention provides a pharmaceutical composition containing a 5-HT<sub>2C</sub> receptor agonist and a 5-HT<sub>6</sub> receptor antagonist for therapeutic use.

10

## BACKGROUND ART

Serotonin (5-hydroxytryptamine or 5-HT) is a key neurotransmitter of the peripheral  
15 and central nervous system (PNS and CNS) and has been implicated in a variety of  
sensory, motor and behavioral functions such as regulation of eating, sleeping, body  
temperature, blood pressure, emotions and cognition. At least 14 distinct serotonin  
receptor subtypes are expressed in the mammalian PNS and CNS and have been  
formally classified; see Glennon, et al., *Neurosci. Biobehav. Rev.* 1990, 14, 35-37; and  
20 D. Hoyer, et al., *Pharmacol. Rev.* 1994, 46, 157-203. Serotonergic agonists and  
antagonists have been suggested for the treatment of a wide range of disorders,  
including anxiety, depression, hypertension, migraine, obesity, drug abuse and  
addiction, compulsive disorders, schizophrenia, autism, neurodegenerative disorders  
(e.g. Alzheimer's disease, Parkinsonism, and Huntington's chorea), and chemotherapy-  
25 induced vomiting.

The 5-HT<sub>2</sub> subfamily of receptors is composed of three subtypes, the 5-HT<sub>2A</sub>, 5-  
HT<sub>2B</sub> and 5-HT<sub>2C</sub> receptors. Serotonin 5-HT<sub>2C</sub> receptors are expressed in many brain  
regions and have been implicated in the regulation of food intake (Dourish, C.T. *Obes.  
Res.* 1995, 3, Suppl. 4, 449S-462S; Bickerdike, M.J., et al. *Diabetes, Obes. Metab.*  
30 1999, 1, 207-214). It has been demonstrated that the non-specific 5-HT<sub>2C</sub> receptor  
agonist *m*-chlorophenylpiperazine (*m*-CPP), which has some preference for the 5-HT<sub>2C</sub>  
receptor, reduces food intake in mice that express the normal 5-HT<sub>2C</sub> receptor while  
the compound lacks activity in mice expressing the mutated inactive form of the  
5-HT<sub>2C</sub> receptor (Tecott, L.H., et al. *Nature* 1995, 374, 542-546).

Moreover, it has been reported that *m*-CPP and the azepinoindole U-22394A, the latter recently identified to be a 5-HT<sub>2C</sub> receptor agonist (unpublished observation), reduce body weight in humans following two and nine weeks of treatment, respectively (Walsh, A. E. S., *Psychopharmacology* 1994, 116, 120-122; Sargent, P.A., et al. *Psychopharmacology* 1997, 133, 309-312 and Gallant, D.M., et al. *Curr. Ther. Res.* 1967, 9, 579-581).

Recently, a series of pyrrolo[3,2,1-*ij*]quinoline derivatives was identified to be 5-HT<sub>2C</sub> receptor agonists having selectivity over the 5-HT<sub>2A</sub> receptor (Isaac M., et al., *Bioorg. Med. Chem. Lett.* 2000, 10, 919-921). The compounds are said to offer a novel approach to the treatment of obesity and epilepsy.

The 5-HT<sub>2C</sub> receptor subtype has also been suggested to be involved in CNS disorders, such as depression and anxiety (Jenck, F., et al. *Expert Opin. Invest. Drugs* 1998, 7, 1587-1599; Leysen, D.C.M. *IDrugs* 1999, 2, 109-120). The 5-HT<sub>2C</sub> receptor subtype has further been suggested to be involved in urinary disorders such as urinary incontinence (Leysen, D.C.M. *IDrugs* 1999, 2, 109-120).

Also the 5-HT<sub>6</sub> receptor (identified in 1993 - Monsma et al., *Mol. Pharmacol.* 1993, 43, 320-327 and Ruat, M. et al. *Biochem. Biophys. Res. Commun.* 1993, 193, 269-276) has been implicated in the regulation of food intake and CNS disorders.

Thus, for example, Bentley, J. C., et al., *Br. J. Pharmacol.* 1999, 126, 66P describes food intake reduction in rats by the administration of a 5-HT<sub>6</sub> antagonist. Also, several antidepressants and atypical antipsychotics display high affinity for the 5-HT<sub>6</sub> receptor which have suggested the involvement of the 5-HT<sub>6</sub> receptor in schizophrenia (Roth et al. *J. Pharmacol. Exp. Ther.* 1994, 268, 1403-1410; Sleight et al. *Expert Opin. Ther. Patents* 1998, 8, 1217-1224; Bourson et al. *Br. J. Pharm.* 1998, 125, 1562-1566; Boess et al. *Mol. Pharmacol.* 1998, 54, 577-583; Sleight et al. *Br. J. Pharmacol.* 1998, 124, 556-562). In addition, the 5-HT<sub>6</sub> receptor has been linked to generalized stress and anxiety states (Yoshioka et al. *Life Sci.* 1998, 17/18, 1473-1477).

## SUMMARY OF THE INVENTION

According to the present invention it has now unexpectedly been found that the combined administration of a 5-HT<sub>2C</sub> receptor agonist and a 5-HT<sub>6</sub> receptor antagonist

reduces food intake by more than the administration of either agonist or antagonist alone. Such combined administration of a 5-HT<sub>2C</sub> receptor agonist and a 5-HT<sub>6</sub> receptor antagonist may offer therapeutic advantages as compared to treatment with either agonist or antagonist alone.

5           One aspect of the present invention therefore provides a pharmaceutical composition comprising an effective amount of a combination of a 5-HT<sub>2C</sub> receptor agonist and a 5-HT<sub>6</sub> receptor antagonist, and optionally a pharmaceutically acceptable carrier.

10           Another aspect of the invention provides a method of preventing or treating a disease, in particular obesity, related to the 5-HT<sub>2C</sub> receptor and the 5-HT<sub>6</sub> receptor, comprising administering to a human or animal subject in need thereof a 5-HT<sub>2C</sub> receptor agonist and a 5-HT<sub>6</sub> receptor antagonist (simultaneously or sequentially) in sufficient amounts to provide a therapeutic effect.

15           Still another aspect of the invention provides the use of a 5-HT<sub>2C</sub> receptor agonist and a 5-HT<sub>6</sub> receptor antagonist for the manufacture of a medicament for the treatment of a disease related to the 5-HT<sub>2C</sub> receptor and the 5-HT<sub>6</sub> receptor.

20           Another aspect of the invention provides a process for preparing a pharmaceutical composition, wherein a 5-HT<sub>2C</sub> receptor agonist and a 5-HT<sub>6</sub> receptor antagonist in a combined therapeutic amount are intimately mixed with a pharmaceutically acceptable carrier.

25           Yet another aspect of the invention provides a product containing a 5-HT<sub>2C</sub> receptor agonist and a 5-HT<sub>6</sub> receptor antagonist as a combined preparation for simultaneous, separate or sequential use in therapy of a disease, in particular obesity, related to the 5-HT<sub>2C</sub> receptor and the 5-HT<sub>6</sub> receptor.

## BRIEF DESCRIPTION OF THE DRAWINGS

30           Figure 1 shows the effect on food intake in ob/ob mice following combined administration with a 5-HT<sub>2C</sub> receptor agonist (PNU-183933F; 50 mg/kg po) and a 5-HT<sub>6</sub> receptor antagonist (PNU-186053A; 50 mg/kg sc), as well as the effect of each agonist and antagonist alone.

Figure 2 shows the effect on food intake in ob/ob mice following combined administration of a 5-HT<sub>2C</sub> receptor agonist (BVT.2938F; 5 mg/kg sc) and a 5-HT<sub>6</sub> receptor antagonist (BVT.5182C; 3 mg/kg sc), as well as the effect of each agonist and antagonist alone.

5

## DETAILED DESCRIPTION OF THE INVENTION

As mentioned above, the present invention is based on the unexpected finding that combined administration of a 5-HT<sub>2C</sub> receptor agonist and a 5-HT<sub>6</sub> receptor antagonist reduces food intake more than either agonist or antagonist alone. Such combined administration of a 5-HT<sub>2C</sub> receptor agonist and a 5-HT<sub>6</sub> receptor antagonist may also offer several benefits, for instance in the treatment of obesity, as compared to treatment with either agonist or antagonist alone.

Firstly, the combined administration requires lower doses of each compound to yield similar or improved reduction of food intake than mono-therapy.

Secondly, the lower doses required by the combined administration may reduce the risk of adverse events.

Thirdly, the lower doses required by the combined administration may reduce the risk of tolerance development and abuse liability.

Fourthly, therapy based on two targets may increase the individual therapeutic efficacy relative to therapy based on one target. The risk of non-responsive efficacy (non-responders) may be reduced as well.

The beneficial effects of the combined administration of this invention is useful not only for the modulation of eating behavior, and for treating over-weight and obesity, but may also be useful for the treatment of CNS disorders such as, depression, mania, schizophreniform disorders, anxiety, memory disorders (such as Alzheimer's disease) migraine headache, drug addiction, convulsive disorders, personality disorders, post-traumatic stress syndrome, and sleep disorders as well as for treatment of urinary incontinence (or more generally overactive bladder), sexual dysfunctions, gastrointestinal disorders and glaucoma.

The term "5-HT<sub>2C</sub> receptor agonist" as used herein refers to a compound that causes activation of the serotonin 5-HT<sub>2C</sub> receptor. The 5-HT<sub>2C</sub> receptor agonist

preferably has an affinity constant,  $K_i$ , of less than 50 nM, preferably less than 20 nM, and an *in vitro* intrinsic activity, measured as intracellular  $\text{Ca}^{2+}$  levels, greater than 20%, preferably greater than 50%, relative to 5-HT (1  $\mu\text{M}$ ).

The term "5-HT<sub>6</sub> receptor antagonist" as used herein refers to a compound that  
5 causes blockade of the serotonin 5-HT<sub>6</sub> receptor mediated responses. The 5-HT<sub>6</sub> receptor antagonist preferably has an affinity constant,  $K_i$ , of less than 50 nM, preferably less than 20 nM, and an *in vitro* intrinsic activity, measured as intracellular cAMP levels, less than 50%, preferably less than 20%, relative to 5-HT (1  $\mu\text{M}$ ).

*In vitro* assays that may be used for determining the affinity and the intrinsic  
10 activity, respectively, of 5-HT<sub>2C</sub> receptor agonists and 5-HT<sub>6</sub> receptor antagonists are known in the art and are also given in the Experimental Part below, as are assays for determining affinity to 5-HT<sub>2A</sub> and 5-HT<sub>2B</sub> receptors.

Generally, the 5-HT<sub>2C</sub> receptor agonists and 5-HT<sub>6</sub> receptor antagonists should be sufficiently selective not to cause any substantial adverse side effects. The terms  
15 "selective" and "substantial" in this context are, however, to be interpreted broadly, the meanings thereof being readily apparent to the skilled person.

The 5-HT<sub>2C</sub> receptor agonist preferably has a selectivity for the 5-HT<sub>2C</sub> receptor of at least 5, preferably at least 10 and more preferably at least 20, relative to the 5-HT<sub>2A</sub>, 5-HT<sub>2B</sub> and 5-HT<sub>6</sub> receptors, respectively (measured as the affinity ratios 5-HT<sub>2A</sub>/5-HT<sub>2C</sub>, 5-HT<sub>2B</sub>/5-HT<sub>2C</sub> and 5-HT<sub>6</sub>/5-HT<sub>2C</sub>).  
20

The 5-HT<sub>6</sub> receptor antagonist preferably has a selectivity for the 5-HT<sub>6</sub> receptor of at least 5, preferably at least 10 and more preferably at least 20, relative to the 5-HT<sub>2A</sub>, 5-HT<sub>2B</sub> and 5-HT<sub>2C</sub> receptors, respectively (measured as the affinity ratios 5-HT<sub>2A</sub>/5-HT<sub>6</sub>, 5-HT<sub>2B</sub>/5-HT<sub>6</sub> and 5-HT<sub>2C</sub>/5-HT<sub>6</sub>).

25 Relevant tests to determine whether a compound is a selective 5-HT<sub>2C</sub> receptor agonist or a selective 5-HT<sub>6</sub> receptor antagonist are known in the art, and are, as mentioned above, also outlined in the Experimental Part below.

Compounds known to be 5-HT<sub>2C</sub> receptor agonists are, for example, azetidine and pyrrolidine derivatives of the type described in EP-A-0863136; tricyclic pyrrole  
30 derivatives of the type described in EP-A-0657426; 1-aminoethylindoles of the type described in EP-A-0655440; pyrazinoindoles of the type described in EP-A-0572863; piperazinyipyrazines of the type described in US 4,081,542; indoline derivatives of the type described in WO 00/12475; pyrroloindoles, pyridoindoles and azepinoindoles of

the type described in WO 00/12510; indazole derivatives of the type described in WO 00/12482; pyrroloquinolines of the type described in WO 00/12502; 2,3,4,4a-tetrahydro-1H-pyrazino[1,2-a]quinoxalin-5(6H)ones of the type described in WO 00/35922; indazolylpropylamines of the type described in WO 00/12481; indazoles of  
5 the type described in WO 00/17170; piperazinyldiazines of the type described in WO 00/76984 and in Swedish patent applications Nos. 0004244-0 and 0004245-7, filed on 20 November 2000; heterocycle fused  $\gamma$ -carboline of the type described in WO 00/77001, WO 00/77002 and WO 00/77010; benzofuryl piperazines of the type described in WO 01/09111 and WO 01/09123; benzofurans of the type described in WO  
10 01/09122; benzothiophenes of the type described in 01/09126; pyridinyl piperazines of the type described in EP 370560; pyrroloquinolines of the type described in Bioorg. Med. Chem. Lett. 2000, 10, 919-921; aminoalkylindazoles of the type described in WO 98/30548; indoles of the type described in WO 01/12603; indolines of the type described in WO 01/12602; pyrazino(aza)indoles of the type described in WO  
15 00/44753; tricyclic pyrroles or pyrazoles of the type described in WO 98/56768.

Currently preferable 5-HT<sub>2C</sub> receptor agonists are of the arylpiperazine and piperazinyldiazine compound classes, in particular compounds disclosed in WO 00/76984 and in Swedish patent applications Nos. 0004244-0 and 0004245-7, filed on 20 November 2000.

20 Compounds known to be 5-HT<sub>6</sub> receptor antagonists are, for example, piperazinyldiazinesulfonamides of the type described in WO 99/37623; sulfonylbenzene derivatives of the type described in EP-A-0930302; sulfonamide derivatives of the type described in WO 99/02502; sulfonamide derivatives of the type described in WO 99/42465; sulfonamide derivatives of the type described in WO  
25 98/27081; carboxamide derivatives of the type described in WO 98/27058; sulfonamide derivatives of the type described in EP-A-0815861; pyrrolidonomethylindole derivatives of the type described in WO 99/47516; bicyclic piperidine and piperazine derivatives of the type described in WO 99/65906; pyrazolopyrimidine and pyrazolotriazine derivatives of the type described in EP-A-0941994; arylsulfone-  
30 substituted hexahydroazepinoindoles of the type described in WO 01/05793; oxazinocarbazoles of the type described in WO 01/09142; aminoalkoxycarbazoles of the type described in WO 01/17963; diphenylsulfones of the type described in the international patent application PCT/US00/30177, filed on June 20, 2000; and



arylsulfonylindoles of the type described in the Swedish patent application No. 0003810-9, filed on October 20, 2000.

Currently preferable 5-HT<sub>6</sub> receptor antagonists include the azepinoindole compound class, such as the class of arylsulfone-substituted hexahydroazepinoindoles compounds disclosed in WO 01/05793. Other preferred 5-HT<sub>6</sub> receptor antagonists include the arylsulfonylindole compound class, such as the compound class described in the Swedish patent application No. 0003810-9.

The 5-HT<sub>2C</sub> receptor agonists and the 5-HT<sub>6</sub> receptor antagonists may be the compounds as such or where appropriate the pharmaceutically acceptable salts (acid or base addition salts) thereof or stereochemically isomeric forms thereof (including optical isomers, such as enantiomers and racemates).

The pharmaceutically acceptable addition salts as mentioned above are meant to comprise the therapeutically active non-toxic acid and base addition salt forms which the compounds are able to form. Compounds which have basic properties can be converted to their pharmaceutically acceptable acid addition salts by treating the base form with an appropriate acid. Exemplary acids include inorganic acids, such as hydrogen chloride, hydrogen bromide, hydrogen iodide, sulphuric acid, phosphoric acid; and organic acids such as acetic acid, propanoic acid, hydroxyacetic acid, lactic acid, pyruvic acid, glycolic acid, maleic acid, malonic acid, oxalic acid, benzenesulfonic acid, toluenesulfonic acid, methanesulfonic acid, trifluoroacetic acid, fumaric acid, succinic acid, malic acid, tartaric acid, citric acid, salicylic acid, p-aminosalicylic acid, pamoic acid, benzoic acid, ascorbic acid and the like. Exemplary base addition salt forms are the sodium, potassium, calcium salts, and salts with pharmaceutically acceptable amines such as, for example, ammonia, alkylamines, benzathine, and amino acids, such as, e.g. arginine and lysine. The term addition salt as used herein also comprises solvates which the compounds and salts thereof are able to form, such as, for example, hydrates, alcoholates and the like.

The 5-HT<sub>2C</sub> receptor agonists and the 5-HT<sub>6</sub> receptor antagonists may also be prodrugs or forms that may release the active ingredient in question after metabolic transformation *in vivo*. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs" ed. H. Bundgaard, Elsevier, 1985.

The 5-HT<sub>2C</sub> receptor agonists and the 5-HT<sub>6</sub> receptor antagonists may be formulated into various pharmaceutical forms for administrative purposes, either in the same pharmaceutical dosage form, such as in the same tablet, or in separate pharmaceutical dosage forms. In the latter case, however, it may be advantageous to put  
5 the 5-HT<sub>2C</sub> receptor agonist unit dosage form and the 5-HT<sub>6</sub> receptor antagonist unit dosage form in the same package, for example in the same blister.

The 5-HT<sub>2C</sub> receptor agonists and the 5-HT<sub>6</sub> receptor antagonists, in the form of free bases or salt, can be brought into suitable galenic forms, such as compositions for oral use, for injection, for nasal spray administration or the like, in accordance with  
10 accepted pharmaceutical procedures. Such pharmaceutical compositions according to the invention comprise an effective amount of a 5-HT<sub>2C</sub> receptor agonist and a 5-HT<sub>6</sub> receptor antagonist in association with compatible pharmaceutically acceptable carrier materials, or diluents, as are well known in the art. The carriers may be any inert material, organic or inorganic, suitable for oral, enteral, rectal, percutaneous,  
15 subcutaneous or parenteral administration, such as: water, gelatin, gum arabicum, lactose, microcrystalline cellulose, starch, sodium starch glycolate, calcium hydrogen phosphate, magnesium stearate, talcum, colloidal silicon dioxide, and the like. Such compositions may also contain other pharmacologically active agents, and conventional additives, such as stabilizers, wetting agents, emulsifiers, flavoring agents, buffers, and  
20 the like.

The compositions according to the invention can e.g. be made up in solid or liquid form for oral administration, such as tablets, pills, capsules, powders, syrups, elixirs, dispersible granules, cachets, suppositories and the like, in the form of sterile solutions, suspensions or emulsions for parenteral administration, sprays, e.g. a nasal  
25 spray, transdermal preparations, e.g. patches, and the like.

The dose level of each of the specific 5-HT<sub>2C</sub> receptor agonist and 5-HT<sub>6</sub> receptor antagonist, and the frequency of dosage of the specific combination will vary depending on a variety of factors including the potency of each specific compound employed, the metabolic stability and length of action of that compound, the patient's  
30 age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the condition to be treated). The daily dosage may, for example, range from about 0.001 mg to about 150 mg per kilo of body weight, preferably from about 0.01 mg to about 100 mg per kilo of body weight,

especially from about 0.1 to about 50 mg per kilo of body weight of each of the 5-HT<sub>2C</sub> receptor agonist and of the 5-HT<sub>6</sub> receptor antagonist, administered singly or multiply in doses, e.g. dosages of from about 0.01 mg to about 1 g each. Usually, such a combined dosage is given orally but e.g. parenteral or rectal administration may also be chosen. An exemplary tablet combination formulation may be in the form of either (A) two separate tablets, i.e. one tablet containing 10 mg, 20 mg or 50 mg of a 5-HT<sub>2C</sub> receptor agonist, and one tablet containing 10 mg, 20 mg or 50 mg of a 5-HT<sub>6</sub> receptor antagonist; or (B) a combined tablet containing 10 mg, 20 mg or 50 mg of a 5-HT<sub>2C</sub> receptor agonist and 10 mg, 20 mg or 50 mg of a 5-HT<sub>6</sub> receptor antagonist.

The invention will now be illustrated further by the following non-limiting Experimental Section.

## EXPERIMENTAL SECTION

### A. Preparation of test compounds

The free base of the 5-HT<sub>2C</sub> receptor agonist *(2R)-methyl-1-{3-[2-(3-pyridinyloxy)ethoxy]-2-pyrazinyl}piperazine, fumarate* ("PNU-183933F") was prepared as described in WO 00/76984. The free base was converted to its fumarate salt, m.p. 126-129°C. MS *m/z* 315 (M)<sup>+</sup>. Anal. (C<sub>16</sub>H<sub>21</sub>N<sub>5</sub>O<sub>2</sub> · C<sub>4</sub>H<sub>4</sub>O<sub>4</sub>) C, H, N.


The 5-HT<sub>6</sub> receptor antagonist *6-methyl-9-(phenylsulfonyl)-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole, hydrochloride* ("PNU-186053A") was prepared as described in WO 01/05793.

The 5-HT<sub>2C</sub> receptor agonist *(2R)-1-(3-{2-[(2-ethoxy-3-pyridinyl)oxy]ethoxy}-2-pyrazinyl)-2-methylpiperazine, fumarate* ("BVT.2938F") was prepared as described in WO 00/76984.

The 5-HT<sub>6</sub> receptor antagonist *1-(phenylsulfonyl)-4-(1-piperazinyl)-1H-indole, hydrochloride* ("BVT.5182C") was prepared as described in Swedish patent application No. 0003810-9, filed on October 20, 2000. Briefly, BVT.5182C was prepared according

the general procedure depicted in Scheme 1, below, starting from commercially available 4-piperazinoindole (compound 1) that undergoes steps (a) to (c) to afford 1-(phenylsulfonyl)-4-(1-piperazinyl)-1*H*-indole, hydrochloride (yield 80%). HPLC purity >95%; <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 9.64 (br s, 2 H), 8.00-7.85 (m, 3 H), 7.79 (d, *J* = 3.77 Hz, 1 H), 7.70-7.65 (m, 1 H), 7.63-7.60 (m, 3 H), 7.27-7.22 (m, 1 H), 6.95 (d, *J* = 3.76 Hz, 1 H), 6.81-6.77 (m, 1 H), 3.30-3.20 (m, 4 H); <sup>13</sup>C NMR (DMSO-*d*<sub>6</sub>) δ 144.79, 137.02, 135.22, 134.62, 129.82, 126.85, 125.63, 125.54, 123.49, 111.15, 107.87, 107.76, 47.81, 42.86; MS (posES-FIA) *m/z* 342 (M+H).

Scheme 1



10 *Step (a): BOC protection of the piperazine N4 nitrogen*

4-Piperazinoindole (1eq), DMAP (0.1 eq) and Et<sub>3</sub>N (4 eq) were dissolved in DMF. (BOC)<sub>2</sub>O (1.1 eq) was added and the reaction mixture was stirred at room temperature (12 h). DMF was evaporated and the residue was purified by chromatography on silica gel using a mixture of chloroform, methanol and ammonia as eluent. HPLC: 100 % purity. MS *m/z* 302.2 (M+H).

*Step (b): Preparation of intermediate 3*

The intermediate 2 (1.0 eq) was dissolved in DMF and NaH (1.3 eq) was added and the suspension was stirred for 0.5 h under nitrogen atmosphere. Benzenesulfonyl chloride (1.2 eq) was added and the reaction was stirred overnight at room temperature. The volatiles were evaporated. The residue was dissolved in DCM, washed with a saturated solution of NaHCO<sub>3</sub>, dried (MgSO<sub>4</sub>), filtered and concentrated to give an oily residue that was purified by chromatography on silica gel using a mixture of hexane and ethylacetate (7:3) as eluent to give tert butyl 4-[1-(benzenesulfonyl)-1*H*-indol-4-yl]-1-

piperazinecarboxylate (3). HPLC 100 %. NMR ( $^1\text{H}$  and  $^{13}\text{C}$ ) and MS analyses support the stated structure.

*Step (c): Removal of the BOC protecting group*

- 5        The BOC group on intermediate 3 was removed by dissolving the compound in methanol followed by addition of ether saturated with HCl gas. The HCl salt (4) was filtered and dried.

**B. Preparation of a pharmaceutical composition**

10

*Tablet*

	<u>Ingredients</u>	<u>mg/tablet</u>
	1. 5-HT <sub>2C</sub> receptor agonist	10.0
	2. 5-HT <sub>6</sub> receptor antagonist	10.0
15	3. Cellulose, microcrystalline	57.0
	4. Calcium hydrogen phosphate	15.0
	5. Sodium starch glycolate	5.0
	6. Silicon dioxide, colloidal	0.25
	7. Magnesium stearate	0.75

20

The active ingredients 1 and 2 are mixed with ingredients 3, 4, 5 and 6 for about 10 minutes. The magnesium stearate (7) is then added, and the resultant mixture is mixed for about 5 minutes and compressed into tablet form with or without film-coating.

25    **C. Receptor affinity and efficacy assays**

*5-HT<sub>2C</sub> receptor affinity assay*

- 30        5-HT<sub>2C</sub> receptor affinity is determined in competition experiments, where the ability of a compound in serial dilution to displace  $^3\text{H}$ -labeled 5-HT, bound to membranes prepared from a transfected HEK293 cell line stably expressing the human 5-HT<sub>2C</sub> receptor protein, is monitored by Scintillation Proximity Assay (SPA) technology. Non-specific binding is defined using 5  $\mu\text{M}$  mianserin.

***5-HT<sub>2A</sub> receptor affinity assay***

5-HT<sub>2A</sub> receptor affinity is determined in competition experiments, where the ability of a compound in serial dilution to displace <sup>3</sup>H-labeled ketanserin or lysergic acid diethylamide (LSD), bound to membranes prepared from a transfected CHO cell line stably expressing the human 5-HT<sub>2A</sub> receptor protein, is monitored by measuring the radioactivity of filtered membrane homogenates on glass fiber filters in a scintillation counter. Non-specific binding is defined using 5 µM mianserin.

***5-HT<sub>2B</sub> receptor affinity assay***

5-HT<sub>2B</sub> receptor affinity is determined in competition experiments, where the ability of a compound in serial dilution to displace <sup>3</sup>H-labeled 5-HT, bound to membranes prepared from a transfected CHO cell line stably expressing the human 5-HT<sub>2B</sub> receptor protein, is monitored by Scintillation Proximity Assay (SPA) technology. Non-specific binding is defined using 5 µM mianserin.

***5-HT<sub>2C</sub> receptor efficacy assay***

The agonist efficacy at the 5-HT<sub>2C</sub> receptor is determined by the ability of a compound to mobilise intracellular calcium in transfected HEK293 cells, stably expressing the human 5-HT<sub>2C</sub> receptor protein, using the calcium-chelating fluorescent dye FLUO-3 (Sigma, St. Louis, MO, U.S.A.). Relative efficacy (%) is measured relative to that of serotonin at 1 µM.

***5-HT<sub>6</sub> receptor affinity assay***

The radioligand binding assay uses [<sup>3</sup>H]-lysergic acid diethylamide (LSD). The assay is carried out in 96-well sample plates by the addition of 11 µl of the test compound at the appropriate dilution (the assay employs 11 serial concentrations of samples run in duplicate), 11 µl of radioligand, and 178 µl of a washed mixture of WGA-coated SPA beads and membranes in binding buffer prepared from HEK293-cells containing cloned human 5-HT<sub>6</sub> receptor. The plates are shaken for about 5 minutes and then incubated at room temperature for 1 hour. The plates are then loaded into counting cassettes and counted in a scintillation counter. The specifically bound cpm obtained are fit to a one-site binding model using GraphPad Prism ver. 2.0.

Estimated IC<sub>50</sub> values are converted to K<sub>i</sub> (affinity constant) values using the Cheng-Prusoff equation (Cheng, Y. C. et al., *Biochem. Pharmacol.* 1973, 22, 3099-3108).

#### *5-HT<sub>6</sub> receptor efficacy assay*

- 5        The antagonist potency at the 5-HT<sub>6</sub> receptor is determined by the ability of a compound to antagonize the increase in cAMP induced by 5-HT in HEK293 cells, stably expressing the human 5-HT<sub>6</sub> receptor protein, using a cAMP SPA direct screening assay system (RPA559, Amersham Pharmacia Biotech, Uppsala, Sweden).

#### 10    **D. Food intake test**

##### *Test compounds*

- 5-HT<sub>2C</sub> receptor agonists (2*R*)-methyl-1-{3-[2-(3-pyridinyloxy)ethoxy]-2-pyrazinyl}piperazine, fumarate ("PNU-183933F") and (2*R*)-1-(3-{2-[(2-ethoxy-3-pyridinyl)oxy]ethoxy}-2-pyrazinyl)-2-methylpiperazine, fumarate ("BVT.2938F") were  
15        dissolved in saline (0.9% NaCl) and diluted in the same vehicle to the appropriate concentration.

- 5-HT<sub>6</sub> receptor antagonists 6-methyl-9-(phenylsulfonyl)-1,2,3,4,5,6-hexahydroazepino[4,5-*b*]indole, hydrochloride ("PNU-186053A") and 1-  
20        (phenylsulfonyl)-4-(1-piperazinyl)-1*H*-indole, hydrochloride (5-HT<sub>6</sub> receptor antagonist ("BVT.5182C")) were dissolved and diluted in 25% cyclodextrin.

Fresh solutions were prepared on the day of treatment.

##### *Animals*

- 25        Male mice 8-9 weeks old (C57BL/6JBom-Lep<sup>ob</sup> (ob/ob), Bomholtsgaard, Denmark) with an average body weight of 45 g were used. The animals were housed singly in cages at 23±1°C, 40-60% humidity and had free access to water and standard laboratory chow. The 12/12 h light/dark cycle was set to lights off at 5 p.m. The animals were conditioned for at least one week before start of study. During  
30        experimental sessions, the animals obtained special chow (BioServ, Frenchtown, NJ, USA dust-free precision pellets weighing 20 mg each).

### *Experimental section*

At the start of the study the animals were transferred to special cages "operant test cages" (Habitest Modular Animal Behavior Test System; Colbourn Instr, Allentown, PA, USA). These cages consist of a feeder trough with sensors for measurement of food intake, an optic lickometer for registration of water intake and an infrared-based monitor for recording overall general motor activity. The monitors are coupled to a computer, which controls and monitor events continuously. Food pellets were weighed to the amount needed for one whole study and water bottles were filled with fresh tap water and weighed. The animals were conditioned to their new environment for three days to establish baseline values. The animals were weighed at 3 p.m. at the start and at the end of the study. The compounds were administered between 4.20 and 5.00 p.m. before dark onset. Three groups of animals received (i) 5-HT<sub>6</sub> antagonist in 25% cyclodextrin; (ii) 5-HT<sub>2C</sub> agonist in saline; and (iii) the combination 5-HT<sub>2C</sub> agonist/5-HT<sub>6</sub> antagonist, respectively. When combined, 5-HT<sub>6</sub> antagonist or saline was administered 30 min before administration of the 5-HT<sub>2C</sub> agonist or 25% cyclodextrin. A fourth group received respectively vehicle administered in the same way. The study ended on the fifth day. Weighing was performed with a computer-assisted Mettler-Toledo PR5002/PR802 balance.

### *Evaluation of results*

Each dose group consisted of 12-16 animals. Data were corrected for food spillage based on the weighed spillage during 22 hours and assumed to be proportional over time. Calculations were performed for the data before and after treatment. The values were expressed as % of basal food intake (mean  $\pm$  SEM) for the difference between food intake before treatment and 3 h (5 pm – 8 pm), 6 h (5 pm – 11 pm), 12 h (5 pm – 5 am), 21 h (5 pm – 2 pm).

The results shown in Fig. 1 indicate that combined treatment with the 5-HT<sub>6</sub> receptor antagonist "PNU-186053A" (50 mg/kg subcutaneously) and the 5-HT<sub>2C</sub> receptor agonist "PNU-183933F" (50 mg/kg per orally) decreased food consumption significantly more than the compounds given alone. Correspondingly, the results shown in Fig. 2 indicate that combined treatment with the 5-HT<sub>2C</sub> receptor agonist "BVT.2938F" (5 mg/kg subcutaneously) and the 5-HT<sub>6</sub> receptor antagonist "BVT.5182C" (3 mg/kg subcutaneously) decreased food consumption, at 12 and 21



hours following administration, significantly more than the compounds given alone. Thus, it is apparent that combined therapy with a 5-HT<sub>2C</sub> receptor agonist and a 5-HT<sub>6</sub> receptor antagonist reduces food intake more efficiently as compared to treatment with either agonist or antagonist alone.

## CLAIMS

1. A pharmaceutical composition comprising an effective amount of a combination of  
a 5-HT<sub>2C</sub> receptor agonist and a 5-HT<sub>6</sub> receptor antagonist, or a salt, enantiomer or  
5 prodrug form of the said agonist and/or antagonist, and optionally a  
pharmaceutically acceptable carrier.
2. The pharmaceutical composition according to claim 1, wherein the 5-HT<sub>2C</sub>  
receptor agonist has a selectivity for the 5-HT<sub>2C</sub> receptor of at least about 10,  
10 preferably at least about 20, relative to the 5-HT<sub>2A</sub> receptor, the 5-HT<sub>2B</sub> receptor,  
and the 5-HT<sub>6</sub> receptor, respectively.
3. The pharmaceutical composition according to claim 1 or 2, wherein the 5-HT<sub>6</sub>  
receptor antagonist has a selectivity for the 5-HT<sub>6</sub> receptor of at least about 10,  
15 preferably at least about 20, relative to the 5-HT<sub>2A</sub> receptor, the 5-HT<sub>2B</sub> receptor  
and the 5-HT<sub>2C</sub> receptor, respectively.
4. The pharmaceutical composition according to claim 1, 2 or 3, wherein the 5-HT<sub>2C</sub>  
receptor agonist is an arylpiperazine compound, such as a piperazinylopyrazine  
20 compound.
5. The pharmaceutical composition according to any one of claims 1 to 4, wherein the  
5-HT<sub>6</sub> receptor antagonist is selected from azepinoindoles, such as arylsulfone-  
substituted hexahydroazepinoindoles, and arylsulfonylindoles.  
25
6. A process for preparing a pharmaceutical composition according to any one of  
claims 1 to 5, wherein a 5-HT<sub>2C</sub> receptor agonist and a 5-HT<sub>6</sub> receptor antagonist  
in a combined therapeutic amount are intimately mixed with a pharmaceutically  
acceptable carrier.  
30
7. A product containing a 5-HT<sub>2C</sub> receptor agonist and a 5-HT<sub>6</sub> receptor antagonist as  
a combined preparation for simultaneous, separate or sequential use in therapy of a  
disease related to the 5-HT<sub>2C</sub> receptor and the 5-HT<sub>6</sub> receptor.

8. The product according to claim 7, wherein the disease is selected from eating disorders, CNS disorders, urinary incontinence and glaucoma.
- 5 9. The product according to claim 8, wherein the disease is over-weight or obesity.
- 10 10. Use of a 5-HT<sub>2C</sub> receptor agonist and a 5-HT<sub>6</sub> receptor antagonist for the manufacture of a medicament for the treatment of a disease related to the 5-HT<sub>2C</sub> receptor and the 5-HT<sub>6</sub> receptor.
11. The use according to claim 10, wherein the disease is selected from eating disorders, CNS disorders, urinary incontinence and glaucoma.
12. The use according to claim 11, wherein the disease is over-weight or obesity.
- 15 13. A method of preventing or treating a disease related to the 5-HT<sub>2C</sub> receptor and the 5-HT<sub>6</sub> receptor, comprising administering to a human or animal subject in need thereof a 5-HT<sub>2C</sub> receptor agonist and a 5-HT<sub>6</sub> receptor antagonist in sufficient amounts to provide a therapeutic effect.
- 20 14. The method according to claim 13, wherein the disease is selected from eating disorders, CNS disorders, urinary incontinence and glaucoma.
15. The method according to claim 14, wherein the disease is over-weight or obesity.
- 25 16. The method according to claim 13, 14 or 15, wherein the 5-HT<sub>2C</sub> receptor agonist and the 5-HT<sub>6</sub> receptor antagonist are administered as a combined pharmaceutical composition.

Fig. 1





Fig. 2



1  
INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 01/01651

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C07C 311/51, A61K 31/18 // A61P 3/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07C, A61K, A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 0012510 A1 (CEREBRUS PHARMACEUTICALS LIMITED), 9 March 2000 (09.03.00), page 1; page 2; page 10, claim 21  --	1-16
X	WO 9827081 A1 (SMITHKLINE BEECHAM PLC), 25 June 1998 (25.06.98), page 1, line 1 - line 16, claims 12,13  --	1-12
A	WO 9965906 A1 (ALLELIX BIOPHARMACEUTICALS INC.), 23 December 1999 (23.12.99), page 3, line 5 - line 10; page 74, claims 33-36  --	

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

16 October 2001

Date of mailing of the international search report

17 -10- 2001

Name and mailing address of the ISA/  
Swedish Patent Office  
Box 5055, S-102 42 STOCKHOLM  
Facsimile No. +46 8 666 02 86

Authorized officer

Fernando Farieta/Eö  
Telephone No. +46 8 782 25 00

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 01/01651

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Journal of Medical Chemistry, Volume 42, No 2, 1999, Cheryl P. Kordik et al, "Pharmacological Treatment of Obesity: Therapeutic Strategies", page 181 - page 201, "Combination Therapy --	1-16
A	Obesity Research, Volume 3, 1995, Collin T. Dourish, "Multiple Serotonin Receptors: Opportunities for New Treatments for Obesity?" page 449 - page 462 --	1-16
A	WO 9942465 A2 (SMITHKLINE BEECHAM PLC), 26 August 1999 (26.08.99), page 7, line 10 - line 25 --	1-16
A	WO 9947516 A1 (SLASSI, ABDELMALIK), 23 Sept 1999 (23.09.99), claims 1-20 --	1-16
A	The Neuroscientist, Volume 6, No 4, 2000, Bryan L. Roth et al, "The Multiplicity of Serotonin Receptors: Uselessly Diverse Molecules or an Embarrassment of Riches?" page 252 - page 262 -- -----	1-16

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/SE01/01651

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 13-16  
because they relate to subject matter not required to be searched by this Authority, namely:  
**See PCT Rule 39.1.(iv) .: Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.**
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.



INTERNATIONAL SEARCH REPORT  
Information on patent family members

01/10/01

International application No.

PCT/SE 01/01651

Patent document cited in search report			Publication date	Patent family member(s)		Publication date
WO	0012510	A1	09/03/00	AU	5637599 A	21/03/00
				EP	1109813 A	27/06/01
				GB	9819035 D	00/00/00
				NO	20010991 A	23/04/01
WO	9827081	A1	25/06/98	AP	9901556 D	00/00/00
				AU	729056 B	25/01/01
				AU	6090498 A	15/07/98
				BG	103530 A	31/01/00
				BR	9713734 A	28/03/00
				CN	1246116 A	01/03/00
				CZ	9902203 A	17/11/99
				EP	0946539 A	06/10/99
				GB	9626377 D	00/00/00
				HU	0000658 A	28/02/01
				IL	130297 D	00/00/00
				JP	2001506646 T	22/05/01
				NO	993003 A	18/06/99
				PL	334337 A	28/02/00
				SK	80899 A	14/02/00
				TR	9901361 T	00/00/00
				TW	418205 B	00/00/00
				ZA	9711319 A	17/06/99
				AU	711629 B	21/10/99
				AU	2172797 A	29/10/97
				GB	9700901 D	00/00/00
				JP	2000507705 T	20/06/00
				GB	9722757 D	00/00/00
WO	9965906	A1	23/12/99	AU	1704997 A	03/08/98
				AU	4253199 A	05/01/00
				AU	4992799 A	14/03/00
				EP	1105393 A	13/06/01
				EP	1108237 A	20/06/01
				US	6251893 B	26/06/01
				WO	0011520 A	02/03/00
				WO	9830374 A	16/07/98
WO	9942465	A2	26/08/99	AU	1047899 A	15/06/99
				EP	1066288 A	10/01/01
				GB	9803411 D	00/00/00
WO	9947516	A1	23/09/99	AU	2821799 A	11/10/99
				US	6100291 A	08/08/00